Baker Brothers Advisors - Q2 2021 holdings

$22.8 Billion is the total value of Baker Brothers Advisors's 120 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 19.0% .

 Value Shares↓ Weighting
SGEN BuySeagen Inc.$7,465,870,000
+13.7%
47,288,259
+0.0%
32.79%
+15.2%
BGNE  BeiGene, Ltd.sponsored adr$4,004,649,000
-1.4%
11,668,8970.0%17.59%
-0.1%
INCY BuyIncyte Corporation$2,693,988,000
+3.6%
32,021,732
+0.1%
11.83%
+4.9%
KOD BuyKodiak Sciences Inc.$1,314,823,000
-16.5%
14,137,881
+1.9%
5.77%
-15.4%
ACAD  ACADIA Pharmaceuticals Inc.$1,022,202,000
-5.5%
41,910,7040.0%4.49%
-4.2%
BMRN  BioMarin Pharmaceutical Inc.$633,251,000
+10.5%
7,589,2940.0%2.78%
+11.9%
ASND  Ascendis Pharma A/Ssponsored adr$465,723,000
+2.1%
3,540,2700.0%2.04%
+3.4%
NVTA SellInvitae Corporation$345,684,000
-42.6%
10,248,575
-34.9%
1.52%
-41.8%
ARGX  argenx SEsponsored adr$337,065,000
+9.3%
1,119,5570.0%1.48%
+10.7%
PRLD  Prelude Therapeutics Incorporated$289,845,000
-33.9%
10,123,8240.0%1.27%
-33.1%
IGMS  IGM Biosciences, Inc.$262,588,000
+8.5%
3,156,1020.0%1.15%
+9.9%
ABCL  AbCellera Biologics Inc.$229,904,000
-35.2%
10,450,1800.0%1.01%
-34.4%
MRTX  Mirati Therapeutics, Inc.$227,722,000
-5.7%
1,409,7840.0%1.00%
-4.5%
BCRX  BioCryst Pharmaceuticals, Inc.$200,958,000
+55.5%
12,710,8180.0%0.88%
+57.7%
MDGL  Madrigal Pharmaceuticals, Inc.$146,038,000
-16.7%
1,499,2130.0%0.64%
-15.7%
APLS BuyApellis Pharmaceuticals, Inc.$143,585,000
+99.9%
2,271,917
+35.7%
0.63%
+102.9%
HRTX BuyHeron Therapeutics, Inc.$126,204,000
+29.9%
8,131,678
+35.6%
0.55%
+31.6%
AMRN  Amarin Corporation plcsponsored adr$115,866,000
-29.5%
26,453,4220.0%0.51%
-28.5%
GBT  Global Blood Therapeutics, Inc.$112,675,000
-14.1%
3,217,4410.0%0.50%
-12.9%
PACB  Pacific Biosciences of California, Inc.$111,973,000
+5.0%
3,201,9720.0%0.49%
+6.5%
IMCR  Immunocore Holdings plcads$98,435,000
-8.3%
2,520,7300.0%0.43%
-7.1%
KYMR  Kymera Therapeutics, Inc.$95,022,000
+24.8%
1,959,2110.0%0.42%
+26.4%
VSTM BuyVerastem, Inc.$87,471,000
+108.1%
21,491,630
+26.3%
0.38%
+111.0%
VERV NewVerve Therapeutics, Inc.$85,346,0001,416,530
+100.0%
0.38%
TLIS  Talis Biomedical Corporation$83,550,000
-14.2%
7,574,8350.0%0.37%
-13.0%
CERS  Cerus Corporation$81,045,000
-1.7%
13,713,1950.0%0.36%
-0.3%
DBVT  DBV Technologies S.A.sponsored adr$79,794,000
+2.4%
14,614,2640.0%0.35%
+3.6%
RYTM BuyRhythm Pharmaceuticals, Inc.$75,642,000
+2.2%
3,863,239
+11.0%
0.33%
+3.4%
TIL  Instil Bio, Inc.$75,226,000
-23.0%
3,893,7000.0%0.33%
-22.0%
LEGN BuyLegend Biotech Corporationsponsored ads$68,329,000
+1936.6%
1,664,534
+1339.6%
0.30%
+1900.0%
NBIX  Neurocrine Biosciences, Inc.$65,883,000
+0.1%
676,9750.0%0.29%
+1.4%
NRIX  Nurix Therapeutics, Inc.$65,107,000
-14.7%
2,454,0820.0%0.29%
-13.6%
INSM  Insmed Incorporated$61,360,000
-16.4%
2,156,0010.0%0.27%
-15.4%
ALLK  Allakos Inc.$60,019,000
-25.6%
703,0500.0%0.26%
-24.6%
ZYME  Zymeworks Inc.$59,267,000
+9.8%
1,708,4720.0%0.26%
+11.1%
HZNP  Horizon Therapeutics Public Ltd Co$56,101,000
+1.7%
599,1100.0%0.25%
+2.9%
FMTX  Forma Therapeutics Holdings, Inc.$50,399,000
-11.2%
2,024,8760.0%0.22%
-10.2%
IMTX BuyImmatics N.V.$49,725,000
+11.1%
4,282,938
+7.3%
0.22%
+12.4%
NewInsmed Incorporatednote 0.75% 6/1/2028$44,063,00040,000,000
+100.0%
0.19%
MRUS  Merus N.V.$42,929,000
+0.9%
2,037,4690.0%0.19%
+2.2%
RARE  Ultragenyx Pharmaceutical Inc.$42,378,000
-16.3%
444,4440.0%0.19%
-15.1%
ADAP  Adaptimmune Therapeutics plcsponsored adr$41,880,000
-19.8%
9,830,8770.0%0.18%
-18.6%
KRYS SellKrystal Biotech, Inc.$41,326,000
-29.5%
607,735
-20.1%
0.18%
-28.7%
KNSA  Kiniksa Pharmaceuticals, Ltd.$38,998,000
-24.7%
2,799,5770.0%0.17%
-24.0%
BuySarepta Therapeutics, Inc.dbcv 1.5% 11/15/2024$38,479,000
+221.5%
29,174,000
+218.0%
0.17%
+225.0%
FLGT  Fulgent Genetics, Inc.$36,986,000
-4.5%
401,0160.0%0.16%
-3.6%
AXSM SellAxsome Therapeutics, Inc.$36,365,000
+2.2%
539,057
-14.2%
0.16%
+3.9%
NLTX  Neoleukin Therapeutics, Inc.$35,275,000
-25.0%
3,821,7400.0%0.16%
-24.0%
BCAB  BioAtla, Inc.$34,964,000
-16.6%
825,0000.0%0.15%
-15.4%
ADCT  ADC Therapeutics SA$34,531,000
-0.2%
1,418,1070.0%0.15%
+1.3%
ALGS  Aligos Therapeutics, Inc.$32,820,000
-10.4%
1,610,0000.0%0.14%
-9.4%
AVTE NewAerovate Therapeutics, Inc.$32,614,0001,428,571
+100.0%
0.14%
RETA  Reata Pharmaceuticals, Inc.cl a$31,699,000
+42.0%
223,9760.0%0.14%
+43.3%
NVAX  Novavax, Inc.$30,521,000
+17.1%
143,7560.0%0.13%
+18.6%
BCEL  Atreca, Inc.$30,099,000
-44.4%
3,532,7600.0%0.13%
-43.8%
ALKS  Alkermes plc$30,115,000
+31.3%
1,228,1700.0%0.13%
+33.3%
DSGN  Design Therapeutics, Inc.$28,575,000
-33.5%
1,436,6360.0%0.12%
-32.8%
NewApellis Pharmaceuticals, Inc.note 3.5% 9/15/2026$27,793,00015,000,000
+100.0%
0.12%
NewTricida, Inc.note 3.5% 5/15/2027$27,332,00075,000,000
+100.0%
0.12%
OPT BuyOpthea Limitedsponsored ads$27,092,000
-14.4%
3,412,062
+3.1%
0.12%
-13.1%
ACHL  Achilles Therapeutics plcsponsored ads$25,369,000
-40.8%
2,591,3660.0%0.11%
-40.3%
AGLE  Aeglea BioTherapeutics, Inc.$23,734,000
-12.1%
3,410,1060.0%0.10%
-11.1%
PTGX SellProtagonist Therapeutics, Inc.$20,433,000
-45.1%
455,276
-68.3%
0.09%
-44.1%
CYT NewCyteir Therapeutics, Inc.$17,390,000812,640
+100.0%
0.08%
CRNX BuyCrinetics Pharmaceuticals, Inc.$17,354,000
+84.2%
920,656
+49.3%
0.08%
+85.4%
OTIC BuyOtonomy, Inc.$16,106,000
-12.5%
7,222,474
+0.0%
0.07%
-11.2%
 BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024$15,566,000
+1.7%
15,000,0000.0%0.07%
+3.0%
KDNY BuyChinook Therapeutics, Inc.$15,255,000
+31.1%
1,080,393
+44.3%
0.07%
+34.0%
AUPH SellAurinia Pharmaceuticals Inc.$14,515,000
-20.7%
1,119,962
-20.6%
0.06%
-19.0%
ALBO  Albireo Pharma, Inc.$14,511,000
-0.2%
412,4660.0%0.06%
+1.6%
 Invitae Corporationnote 2.0% 9/1/2024$13,890,000
-10.7%
10,300,0000.0%0.06%
-9.0%
XENE  Xenon Pharmaceuticals Inc.$13,996,000
+4.0%
751,6390.0%0.06%
+5.2%
ANAB  AnaptysBio, Inc.$11,077,000
+20.3%
427,1790.0%0.05%
+22.5%
MIRM  Mirum Pharmaceuticals, Inc.$11,192,000
-12.8%
647,3130.0%0.05%
-12.5%
EWTX  Edgewise Therapeutics, Inc.$10,665,000
-34.4%
500,0000.0%0.05%
-32.9%
ALT SellAltimmune, Inc.$10,560,000
-72.9%
1,072,038
-61.1%
0.05%
-72.8%
CBAY  Cymabay Therapeutics, Inc.$9,463,000
-4.0%
2,170,4640.0%0.04%
-2.3%
GTH  Genetron Holdings Limitedads$9,170,000
-6.2%
455,3060.0%0.04%
-4.8%
ISEE  IVERIC bio, Inc.$8,872,000
+2.1%
1,406,0370.0%0.04%
+2.6%
CNTA NewCentessa Pharmaceuticals plcsponsored ads$8,884,000400,000
+100.0%
0.04%
ATHA  Athira Pharma, Inc.$8,257,000
-44.3%
806,3670.0%0.04%
-43.8%
ASMB BuyAssembly Biosciences, Inc.$8,181,000
+15.4%
2,108,621
+36.8%
0.04%
+16.1%
KRTX  Karuna Therapeutics, Inc.$7,975,000
-5.2%
69,9660.0%0.04%
-2.8%
MREO SellMereo BioPharma Group plcads$7,796,000
-65.6%
2,459,399
-63.4%
0.03%
-65.3%
BLUE  bluebird bio, Inc.$7,259,000
+6.1%
226,9880.0%0.03%
+6.7%
SBTX  Silverback Therapeutics, Inc.$7,355,000
-29.2%
238,0950.0%0.03%
-28.9%
DNLI  Denali Therapeutics Inc.$6,961,000
+37.4%
88,7380.0%0.03%
+40.9%
RVMD  Revolution Medicines, Inc.$7,053,000
-30.8%
222,2220.0%0.03%
-29.5%
CHMA BuyChiasma, Inc.$6,720,000
+189.3%
1,420,740
+91.4%
0.03%
+200.0%
HOOK  HOOKIPA Pharma Inc.$6,416,000
-31.9%
700,4810.0%0.03%
-31.7%
BNR  Burning Rock Biotech Limitedsponsored ads$6,161,000
+9.4%
209,1310.0%0.03%
+12.5%
REPL  Replimune Group, Inc.$5,898,000
+25.9%
153,5120.0%0.03%
+30.0%
NGM  NGM Biopharmaceuticals, Inc.$5,754,000
-32.2%
291,8010.0%0.02%
-32.4%
CABA  Cabaletta Bio, Inc.$5,473,000
-22.5%
636,3630.0%0.02%
-22.6%
MGNX  MacroGenics, Inc.$5,390,000
-15.7%
200,6790.0%0.02%
-14.3%
ORTX BuyOrchard Therapeutics plcads$5,233,000
-1.9%
1,192,003
+62.3%
0.02%0.0%
ALEC  Alector, Inc.$4,983,000
+3.4%
239,2280.0%0.02%
+4.8%
NEXI  NexImmune, Inc.$4,800,000
-14.5%
294,1170.0%0.02%
-12.5%
BMEA NewBiomea Fusion, Inc.$4,591,000294,117
+100.0%
0.02%
ITOS  Iteos Therapeutics, Inc.$3,856,000
-25.0%
150,3460.0%0.02%
-22.7%
GMDA SellGamida Cell Ltd.$3,914,000
-53.4%
610,626
-41.1%
0.02%
-52.8%
HRMY  Harmony Biosciences Holdings, Inc.$3,489,000
-14.6%
123,6000.0%0.02%
-16.7%
TCDA  Tricida, Inc.$3,151,000
-18.3%
729,3000.0%0.01%
-17.6%
AKRO  Akero Therapeutics, Inc.$2,937,000
-14.5%
118,3780.0%0.01%
-13.3%
TCRR  TCR2 Therapeutics Inc.$2,896,000
-25.7%
176,4610.0%0.01%
-23.5%
EVFM  Evofem Biosciences, Inc.$3,048,000
-35.4%
2,697,1100.0%0.01%
-35.0%
TVTX  Travere Therapeutics, Inc.$2,727,000
-41.6%
186,9150.0%0.01%
-40.0%
XLRN  Acceleron Pharma Inc.$2,815,000
-7.5%
22,4300.0%0.01%
-7.7%
RLMD NewRelmada Therapeutics, Inc.$2,452,00076,600
+100.0%
0.01%
TARA  Protara Therapeutics, Inc.$1,945,000
-38.1%
199,6710.0%0.01%
-35.7%
LOGC  LogicBio Therapeutics, Inc.$2,005,000
-39.0%
451,4780.0%0.01%
-35.7%
INZY  Inozyme Pharma, Inc.$1,823,000
-14.0%
106,9990.0%0.01%
-11.1%
PASG SellPassage Bio, Inc.$1,551,000
-62.3%
117,161
-50.2%
0.01%
-61.1%
AFMD  Affimed N.V.$1,399,000
+7.5%
164,6050.0%0.01%0.0%
OYST  Oyster Point Pharma, Inc.$1,056,000
-6.0%
61,4240.0%0.01%0.0%
 Bellicum Pharmaceuticals, Inc.$822,000
-12.3%
249,1230.0%0.00%0.0%
LPTX  Leap Therapeutics, Inc.$918,000
-13.6%
559,7050.0%0.00%
-20.0%
KZR  Kezar Life Sciences, Inc.$758,000
-8.9%
139,6760.0%0.00%
-25.0%
SYRS SellSyros Pharmaceuticals, Inc.$357,000
-93.1%
65,497
-90.5%
0.00%
-90.9%
FREQ  Frequency Therapeutics, Inc.$553,000
+4.7%
55,5550.0%0.00%0.0%
GNFT ExitGenfit SAads$0-14,720
-100.0%
0.00%
IFRX ExitInflarx N.V.$0-138,040
-100.0%
-0.00%
ADMS ExitAdamas Pharmaceuticals, Inc.$0-147,996
-100.0%
-0.00%
GLMD ExitGalmed Pharmaceuticals Ltd.$0-184,927
-100.0%
-0.00%
GLPG ExitGalapagos NVsponsored adr$0-11,180
-100.0%
-0.00%
MTEM ExitMolecular Templates, Inc.$0-133,833
-100.0%
-0.01%
VKTX ExitViking Therapeutics, Inc.$0-363,980
-100.0%
-0.01%
AUTL ExitAutolus Therapeutics plcsponsored ads$0-461,726
-100.0%
-0.01%
IDRA ExitIdera Pharmaceuticals, Inc.$0-2,047,180
-100.0%
-0.01%
CNST ExitConstellation Pharmaceuticals, Inc.$0-114,735
-100.0%
-0.01%
SRPT ExitSarepta Therapeutics, Inc.$0-58,700
-100.0%
-0.02%
SGMO ExitSangamo Therapeutics, Inc.$0-429,063
-100.0%
-0.02%
XNCR ExitXencor, Inc.$0-369,370
-100.0%
-0.07%
CCXI ExitChemoCentryx, Inc.$0-656,710
-100.0%
-0.15%
ALXN ExitAlexion Pharmaceuticals, Inc.$0-3,993,312
-100.0%
-2.65%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-08-16
Signatures

The EDGAR filing(s) were signed by:

About Baker Brothers Advisors

Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.

Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.

The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.

Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Incyte Corporation42Q3 202337.6%
ACADIA Pharmaceuticals Inc.42Q3 202310.9%
Biomarin Pharmaceuticals Inc.42Q3 20235.9%
BioCryst Pharmaceuticals, Inc.42Q3 20231.7%
Cerus Corporation42Q3 20230.9%
Insmed Incorporated42Q3 20230.4%
Mirati Therapeutics, Inc.41Q3 20231.8%
Bluebird Bio Inc.41Q3 20230.3%
Heron Therapeutics, Inc.39Q3 20231.5%
ChemoCentryx, Inc.37Q3 20220.6%

View Baker Brothers Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Baker Brothers Advisors Q2 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Neoleukin Therapeutics, Inc.August 17, 20239,469,83820.0%
Mereo Biopharma Group plcAugust 10, 202314,604,3912.2%
Verastem, Inc.August 10, 2023? ?
TScan Therapeutics, Inc.June 02, 20232,793,9386.5%
ACADIA PHARMACEUTICALS INCMay 24, 202343,084,28026.5%
INCYTE CORPMarch 15, 202336,280,96716.3%
Seagen Inc.March 13, 202346,985,65625.1%
Talis Biomedical CorpMarch 10, 202337,569,14066.2%
Aeglea BioTherapeutics, Inc.February 14, 20236,384,0139.9%
Merus N.V.February 14, 2023? ?

View Baker Brothers Advisors's complete significant-ownership history.

Latest filings
TypeFiled
42024-03-25
SC 13D/A2024-03-25
42024-03-14
32024-03-07
42024-03-07
SC 13D2024-03-05
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Baker Brothers Advisors's complete filings history.

Compare quarters

Export Baker Brothers Advisors's holdings